Location · Kansas City, KS
Clinical trials in Kansas City, KS
148 recruiting studies have a site in Kansas City, and 30 of them accept healthy volunteers.
148 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- Recruiting
The Impact of MeMed BV® on Management of Patients With Suspected Lower Respiratory Tract Infections (LRTI) in the Emergency Department (ED) and Urgent Care Center (UCC) ("JUPITER" TRIAL)
MeMed Diagnostics Ltd.
- Location
- Kansas City, KS + 7 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 1
A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I…
Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
- Location
- Kansas City, KS + 12 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Incyte Corporation
- Location
- Kansas City, KS + 36 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 2/Phase 3
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
Alkermes, Inc.
- Location
- Kansas City, KS + 32 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
Dianthus Therapeutics
- Location
- Kansas City, KS + 29 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
AstraZeneca
- Location
- Kansas City, KS + 53 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 2
An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy
Teva Branded Pharmaceutical Products R&D LLC
- Location
- Kansas City, KS + 9 other US sites
- Eligibility basics
- Ages 30+
- RecruitingPhase 3
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
Xenon Pharmaceuticals Inc.
- Location
- Kansas City, KS + 44 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 2
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
AllRock Bio, Inc.
- Location
- Kansas City, KS + 10 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
Alkermes, Inc.
- Location
- Kansas City, KS + 21 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
Alkermes, Inc.
- Location
- Kansas City, KS + 21 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 1/Phase 2
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Cabaletta Bio
- Location
- Kansas City, KS + 17 other US sites
- Eligibility basics
- Ages 12–65
- RecruitingPhase 2
ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Calico Life Sciences LLC
- Location
- Kansas City, KS + 33 other US sites
- Eligibility basics
- Ages 18–55
- RecruitingPhase 2
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
Spyre Therapeutics, Inc.
- Location
- Kansas City, KS + 25 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
Hoffmann-La Roche
- Location
- Kansas City, KS + 52 other US sites
- Eligibility basics
- Ages 50–85
- RecruitingPhase 2
A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma
Kymera Therapeutics, Inc.
- Location
- Kansas City, KS + 30 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
Appello Pharmaceuticals, Inc.
- Location
- Kansas City, KS + 29 other US sites
- Eligibility basics
- Ages 30–80
- RecruitingPhase 2
Phase 2 Study to Assess the Safety and Efficacy of ANG003
Anagram Therapeutics, Inc.
- Location
- Kansas City, KS + 19 other US sites
- Eligibility basics
- Ages 12+
- Recruiting
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
Orchestra BioMed, Inc
- Location
- Kansas City, KS + 15 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
ELEVATE-HFpEF Clinical Study
Medtronic Cardiac Rhythm and Heart Failure
- Location
- Kansas City, KS + 25 other US sites
- Eligibility basics
- Ages 40+
- RecruitingPhase 2
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
Neuron23 Inc.
- Location
- Kansas City, KS + 43 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 2
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
Avalyn Pharma Inc.
- Location
- Kansas City, KS + 30 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
AstraZeneca
- Location
- Kansas City, KS + 15 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 2
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
Celgene
- Location
- Kansas City, KS + 13 other US sites
- Eligibility basics
- Ages 18–70